Adjuvant Chemotherapy in Bladder Cancer

Smith, Philip H.

doi:10.1177/014107688107400720

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…others (Wallace, 1973;Williams et al, 1977;Smith, 1981). Hinman (1956) reported 3 cases of tumour recurrence at the bladder neck when it had been resected for obstructive symptoms at the same time as a tumour.…”

Section: Discussionmentioning

confidence: 99%

Cystoscopic Suction Diathermy for the Treatment of Superficial Bladder Tumours

Bunce

Sarmah

Considine

1991

British Journal of Urology

View full text Add to dashboard Cite

The treatment of superficial bladder tumours (Ta, T1) is a time-consuming exercise for urological surgeons and patients. A method of treating the tumours, whether primary or recurrent, by endoscopic suction diathermy has been developed. The technique significantly reduces the amount of tumour debris within the bladder during treatment as well as the amount of diathermy employed. By removing the free tumour cells in the irrigation fluid the risk of tumour cell implantation may be kept to a minimum.

show abstract

Section: Discussionmentioning

confidence: 99%

Cystoscopic Suction Diathermy for the Treatment of Superficial Bladder Tumours

Bunce

Sarmah

Considine

1991

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Die M-Rate ist zwar T-und N-abhängig. aber der Nach weis von hämatogenen Metastasen macht die N-Diagnostik entbehrlich und dient bei einer Chemotherapie als onkologischer Marker [Smith, 1981].…”

Section: Materials Und Methodeunclassified

Parameter der Inkurabilität des Harnblasenkarzinoms

Egghart¹,

Schutz²,

Altwein³

1985

Urol Int

View full text Add to dashboard Cite

Curative treatment of bladder cancer is limited to superficial tumors (T_a––T₂). Advanced stages (T_3a+T_3b) can be treated only palliatively even when confined to the bladder (N₀, M₀). Nevertheless the differentiation between curable and incurable tumors is difficult. The classification of patients into the two different categories is usually done on the basis of tumor infiltration and lymph node involvement. In this retrospective study all available data of patients with bladder cancer were evaluated for their prognostic reliability in order to obtain a safe basis for further therapeutic approaches. The principal aim was to define parameters of reliable prognostic significance to prevent under- or overtreatment during the entire course of the disease.

show abstract

“…CDDP is the most active single agent in the treatment of testicular tumours, and approximately 80% of metastatic testicular germ-cell tumours are curable (Peckham, 1988). In contrast, tumours derived from transitional cells in the bladder are seldom eradicated by chemotherapy, and periods of remission are usually short (Smith, 1981). Comparisons of cellular sensitivity have shown that testicular cell lines are more sensitive than bladder cell lines to cytotoxic drugs, suggesting inherent biochemical differences in the response of the cells to CDDP (Walker et al, 1987).…”

Section: Cell Linementioning

confidence: 99%

Binding activities of cis‐platin‐damage‐recognition proteins in human tumour cell lines

McLaughlin

Coren²,

Masters³

et al. 1993

Intl Journal of Cancer

View full text Add to dashboard Cite

Proteins can be detected by South-western analyses of human tumour-cell extracts binding to double-stranded oligonucleotide DNA treated in vitro with the chemotherapeutic drug cis-diamminedichloroplatinum (II) (CDDP), but not to untreated DNA. The relative molecular masses of proteins binding to the CDDP-treated double-stranded oligonucleotide are 25, 48 and 97 kDa. The binding activity of 2 of the CDDP-damage-recognition proteins, of relative molecular mass 48 and 97 kDa, is greater in a CDDP-resistant human ovarian tumour cell line than in the parental sensitive line. South-western analysis of a panel of human bladder cell lines and CDDP-sensitive testicular cell lines show consistent patterns of CDDP-damage-recognition proteins within each cell type, however with differences between the 2 cell types. Binding of the proteins to CDDP-damaged DNA and the altered binding activity detected in tumour cell lines suggests that alteration in damage-recognition proteins could play a role in tumour response to CDDP.

show abstract

Adjuvant Chemotherapy in Bladder Cancer

Cited by 4 publications

References 17 publications

Cystoscopic Suction Diathermy for the Treatment of Superficial Bladder Tumours

Cystoscopic Suction Diathermy for the Treatment of Superficial Bladder Tumours

Parameter der Inkurabilität des Harnblasenkarzinoms

Binding activities of cis‐platin‐damage‐recognition proteins in human tumour cell lines

Contact Info

Product

Resources

About